PET/MR for Prostate Cancer Restaging: a Phase II Prospective Monocentric Study
Prostate Cancer
About this trial
This is an interventional diagnostic trial for Prostate Cancer focused on measuring prostate cancer, biochemical recurrence, PET/MR
Eligibility Criteria
Inclusion Criteria: Patients with histological proven diagnosis of prostate cancer. Patients treated with radical therapy (RP o EBRT, with or without further adjuvant therapies), who present rising serum PSA values ≥ 0.2 ng/mL. Age ≥ 18 years-old. Willing to provide a signed informed consent. Exclusion Criteria: Age < 18 years-old. Previous and/or concomitant androgen deprivation therapy will be excluded. Any additional medical condition that may significantly interfere with study compliance. Contraindications to MR study (i.e. Pacemaker
Sites / Locations
- IRCCS Ospedale San Raffaele
Arms of the Study
Arm 1
Experimental
Dual tracer PET/MRI
All patients undergo PET/MRI with 68Ga-PSMA and 68Ga-DOTA-RM2. 68Ga-PSMA dose: 160 +-50 MBq, route of administration: intravenous 68Ga-DOTA-RM2 dose: 140 +-50 MBq, route of administration: intravenous